Clinical Trial Update: Life's End Benefits of cannaBidiol and tetrahYdrocannabinol [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on cannabidiol and tetrahydrocannabinol for agitation in dementia; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia

Drugs mentioned

• Cannabidiol (cannabidiol)
• Tetrahydrocannabinol (delta-9-tetrahydrocannabinol)

Snippet

Sponsor: University of Southern California | Conditions: Agitation, Dementia | Phase 2 | Status: ACTIVE_NOT_RECRUITING